

**GF/B45/EDP17**      **Approval of the Secretariat's Recommendation on Funding from the COVID-19 Response Mechanism (Mali, Mozambique and South Africa)**

Approved on 2 September 2021

The Board:

1. Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism ("C19RM") awards exceeding US\$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);
2. Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER16; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.

This decision does not raise new, material budgetary implications for operating expenses.

**Table 1: Secretariat's Recommendation on Funding from C19RM<sup>1</sup>**

Please note that each country name is [linked](#) to the extranet site where relevant supporting documents are available for review.

Country / Multicountry	Grant name	Currency	C19RM 2020 carry-over amount <sup>2</sup>	Previously approved C19RM 2021 award <sup>3</sup>	C19RM 2021 recommended amount for Board approval	Total C19RM 2021 funding	% of 2020-2022 allocation	Total C19RM 2021 funding plus C19RM 2020 carry-over	C19RM Unfunded Demand
<a href="#">Mali</a>	MLI-C-ARC	EUR	0	0	258,260	37,313,389	23.0%	37,313,389	0
	MLI-M-CRS	EUR	0	0	3,749,455				
	MLI-S-MOH	EUR	0	4,552,315	28,753,360				
<a href="#">Mozambique</a>	MOZ-C-CCS	US\$	0	0	5,245,568	100,578,695	13.4%	117,274,209	37,713,279
	MOZ-H-FDC	US\$	731,175	0	5,008,147				
	MOZ-H-MOH	US\$	15,821,758	20,120,458	63,988,318				
	MOZ-M-MOH	US\$	0	0	860,558				
	MOZ-M-WV	US\$	142,582	0	4,825,243				
	MOZ-T-MOH	US\$	0	0	530,402				

<sup>1</sup> The C19RM Investment Committee recommends C19RM Full Funding Requests awards of more than US\$35 million to the Global Fund Board for approval. This amount, measured in aggregate per country, does not include any funding awarded through the C19RM Fast-track process or through C19RM in 2020. The C19RM Investment Committee may also recommend awards under US\$35 million to the Global Fund Board for approval where it determines that the non-health product components of an award are of a nature and scale which raise significant concerns about risk and complexity.

<sup>2</sup> Estimated funds remaining from C19RM 2020 awards previously approved by the C19RM Investment Committee and carried over to this new award.

<sup>3</sup> This includes Secretariat approved Fast-track and Full Funding awards, as well as awards previously approved by the Board.

South Africa	ZAF-C-AFSA	US\$	1,978,802	0	19,949,856	161,029,989	30.0%	172,735,620	5,712,676
	ZAF-C-BZ	US\$	1,295,477	0	10,892,168				
	ZAF-C-NACOSA	US\$	1,874,302	0	25,711,566				
	ZAF-C-NDOH	US\$	6,557,051	0	104,476,400				